
07/22/2025
A world-first lung cancer vaccine has officially entered human trials.
In a historic step toward revolutionizing cancer treatment, doctors have launched the world’s first clinical trial of an mRNA vaccine for lung cancer.
Developed by BioNTech—the same company behind one of the COVID-19 vaccines—this new jab, called BNT116, targets non-small cell lung cancer (NSCLC), the most common and deadliest form of the disease.
The vaccine is designed to train the immune system to recognize and destroy cancer cells and prevent their return, offering hope for thousands facing the often grim prognosis of advanced lung cancer.
The phase 1 trial is being conducted at 34 sites across seven countries, including the UK, US, and Germany.